226 related articles for article (PubMed ID: 34458995)
1. Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
Schenker C; Hirzel C; Walti LN; Zeerleder SS; Andres M; Ramette A; Barbani MT; Suter-Riniker F; Holbro A; Tritschler T
Br J Haematol; 2022 Feb; 196(3):e27-e29. PubMed ID: 34458995
[No Abstract] [Full Text] [Related]
2. Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).
Malsy J; Veletzky L; Heide J; Hennigs A; Gil-Ibanez I; Stein A; Lütgehetmann M; Rosien U; Jasper D; Peine S; Hiller J; Haag F; Schmiedel S; Huber S; Jordan S; Addo MM; Schulze Zur Wiesch J
Clin Infect Dis; 2021 Dec; 73(11):e4020-e4024. PubMed ID: 33103195
[TBL] [Abstract][Full Text] [Related]
3. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e731-e735. PubMed ID: 34217677
[TBL] [Abstract][Full Text] [Related]
4. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019.
Martinot M; Jary A; Fafi-Kremer S; Leducq V; Delagreverie H; Garnier M; Pacanowski J; Mékinian A; Pirenne F; Tiberghien P; Calvez V; Humbrecht C; Marcelin AG; Lacombe K
Clin Infect Dis; 2021 Oct; 73(7):e1762-e1765. PubMed ID: 32986807
[TBL] [Abstract][Full Text] [Related]
5. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
[No Abstract] [Full Text] [Related]
6. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
7. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
[TBL] [Abstract][Full Text] [Related]
8. A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma.
Iaboni A; Wong N; Betschel SD
J Clin Immunol; 2021 Jul; 41(5):923-925. PubMed ID: 33547548
[No Abstract] [Full Text] [Related]
9. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic or relapsing COVID-19 in immunodeficiency.
Brown LK; Moran E; Goodman A; Baxendale H; Bermingham W; Buckland M; AbdulKhaliq I; Jarvis H; Hunter M; Karanam S; Patel A; Jenkins M; Robbins A; Khan S; Simpson T; Jolles S; Underwood J; Savic S; Richter A; Shields A; Brown M; Lowe DM
J Allergy Clin Immunol; 2022 Feb; 149(2):557-561.e1. PubMed ID: 34780850
[TBL] [Abstract][Full Text] [Related]
11. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
[TBL] [Abstract][Full Text] [Related]
12. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
Ali S; Khalid S; Afridi M; Akhtar S; Khader YS; Akhtar H
JMIR Public Health Surveill; 2021 May; 7(5):e27609. PubMed ID: 34009133
[TBL] [Abstract][Full Text] [Related]
13. Update Alert 2: Remdesivir for Adults With COVID-19.
Kaka AS; MacDonald R; Linskens EJ; Wilt TJ
Ann Intern Med; 2021 Dec; 174(12):W114-W115. PubMed ID: 34606312
[No Abstract] [Full Text] [Related]
14. Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).
Pallotto C; Suardi LR; Gabbuti A; Esperti S; Mecocci L; Blanc P
J Med Virol; 2021 May; 93(5):2631-2634. PubMed ID: 33620107
[No Abstract] [Full Text] [Related]
15. Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany-An Ethical Analysis.
Voit K; Timmermann C; Steger F
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073254
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.
Rüfenacht S; Gantenbein P; Boggian K; Flury D; Kern L; Dollenmaier G; Kohler P; Albrich WC
Infection; 2022 Jun; 50(3):783-790. PubMed ID: 35426564
[TBL] [Abstract][Full Text] [Related]
17. Treating COVID-19 Acute Severe Hypoxemic Respiratory Failure: First Case Report Utilizing Dexamethasone, Remdesivir, and Convalescent Plasma in Operation Inherent Resolve.
Gibson RL; Sletten ZJ; Sarkisian SA; Sjulin TJ
Med J (Ft Sam Houst Tex); 2021; (PB 8-21-01/02/03):28-33. PubMed ID: 33666909
[TBL] [Abstract][Full Text] [Related]
18. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
[No Abstract] [Full Text] [Related]
19. Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California's Central Valley.
Padilla R; Arquiette J; Mai Y; Singh G; Galang K; Liang E
J Pharm Pharm Sci; 2021; 24():210-219. PubMed ID: 33939951
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
